SBBP - Strongbridge issued patent for RECORLEV in treatment of Cushing's Syndrome

Strongbridge Biopharma (SBBP) announces that the United States Patent and Trademark Office ((USPTO)) has issued U.S. Patent No. 11,020,393 covering a method of treating certain Cushing’s syndrome patients with RECORLEV (levoketoconazole).The term of the U.S. patent will expire on March 2, 2040.RECORLEV is an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the U.S. FDA for the treatment of endogenous Cushing’s syndrome, a rare, serious and potentially lethal endocrine disease.

For further details see:

Strongbridge issued patent for RECORLEV in treatment of Cushing’s Syndrome